BMY
PFE
New pharmacy lane, same old blockbuster
Pfizer and Bristol Myers Squibb are taking Eliquis, one of the biggest blood thinner franchises on the planet, and giving it a new home at Mark Cuban Cost Plus Drug Company. Translation: the companies are trying to make the drug easier to buy without the usual sticker-shock drama.
Why this matters
This isn’t a flashy launch with confetti and a robot dog. It’s a distribution move. But for investors, distribution is where the money lives or dies, especially for a product like Eliquis that’s still a major cash generator and also sits right in the crosshairs of drug-pricing scrutiny.
The economics game
By showing up in a cheaper, more transparent channel, Pfizer and BMS may protect volume even if the margin story gets a little less glamorous. That’s the tradeoff: a little less ‘premium brand’ energy, a little more ‘let’s keep the script count rolling.’
- Eliquis gets broader access through a lower-cost platform
- Pfizer and BMS keep pushing a top-selling asset where patients are hunting for affordability
- The move helps the companies look more consumer-friendly at a time when pharma pricing is under a microscope
Big picture
This is what mature blockbuster management looks like in 2026: not just making the pill, but making sure people can actually get it without rage-clicking a pharmacy app. For Pfizer, any strategy that helps Eliquis stay sticky is worth watching.